Key Insights

Highlights

Treatment Research

3 treatments under study, led by Pembrolizumab

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Phase 1 (2)

Trial Status

Recruiting1
Active Not Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT05856981Phase 1Recruiting

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

NCT02974738Phase 1Active Not Recruiting

A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

Showing all 2 trials

Research Network

Common Treatments

  • Pembrolizumab1
  • Adu18051
  • Belzutifan1

Active Sponsors

  • Sairopa B.V.1
  • Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)1

Related Conditions

  • Solid Tumor Adult2
  • Advanced Solid Tumors2
  • Nsclc Advanced Nonsmall Cell Lung Cancer1
  • Crc Colorectal Cancer1
  • Renal Cell Carcinoma Metastatic1

Activity Timeline